Read More 1 minute read Analyst Ratings News Price Target Reiteration Needham Reiterates Buy on BigCommerce Holdings, Maintains $20 Price Target By Benzinga Newsdesk February 24, 8:07 AM Needham analyst Scott Berg reiterates BigCommerce Holdings (NASDAQ:BIGC) with a Buy and maintains $20 price target. BIGC
Read More 1 minute read Analyst Ratings News Price Target Reiteration EF Hutton Reiterates Buy on Alnylam Pharmaceuticals, Maintains $304 Price Target By Benzinga Newsdesk February 24, 8:05 AM EF Hutton analyst Michael King reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintains $304 price target. ALNY
Read More 1 minute read Analyst Ratings News Price Target Reiteration Needham Reiterates Buy on Shutterstock, Maintains $90 Price Target By Benzinga Newsdesk February 24, 8:00 AM Needham analyst Bernie McTernan reiterates Shutterstock (NYSE:SSTK) with a Buy and maintains $90 price target. SSTK
Read More 1 minute read Analyst Ratings News Price Target Reiteration Needham Reiterates Buy on Alkami Technology, Maintains $20 Price Target By Benzinga Newsdesk February 24, 7:40 AM Needham analyst Mayank Tandon reiterates Alkami Technology (NASDAQ:ALKT) with a Buy and maintains $20 price target. ALKT
Read More 1 minute read Analyst Ratings News Price Target Reiteration Needham Reiterates Buy on Definitive Healthcare, Maintains $15 Price Target By Benzinga Newsdesk February 24, 7:39 AM Needham analyst Ryan MacDonald reiterates Definitive Healthcare (NASDAQ:DH) with a Buy and maintains $15 price target. DH
Read More 1 minute read Analyst Ratings News Price Target Reiteration Needham Reiterates Buy on Universal Display, Maintains $148 Price Target By Benzinga Newsdesk February 24, 7:31 AM Needham analyst James Ricchiuti reiterates Universal Display (NASDAQ:OLED) with a Buy and maintains $148 price target. OLED
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $25 Price Target By Benzinga Newsdesk February 24, 7:29 AM HC Wainwright & Co. analyst Emily Bodnar reiterates BriaCell Therapeutics (NASDAQ:BCTX) with a Buy and maintains $25 price target. BCTX
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Arvinas, Maintains $90 Price Target By Benzinga Newsdesk February 24, 7:20 AM HC Wainwright & Co. analyst Andrew Fein reiterates Arvinas (NASDAQ:ARVN) with a Buy and maintains $90 price target. ARVN
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on C4 Therapeutics, Maintains $35 Price Target By Benzinga Newsdesk February 24, 7:19 AM HC Wainwright & Co. analyst Andrew Fein reiterates C4 Therapeutics (NASDAQ:CCCC) with a Buy and maintains $35 price target. CCCC
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Kymera Therapeutics, Maintains $85 Price Target By Benzinga Newsdesk February 24, 7:17 AM HC Wainwright & Co. analyst Andrew Fein reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and maintains $85 price target. KYMR